Benchmark Reiterates Speculative Buy on Biolase, Maintains $0.4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on Biolase (NASDAQ:BIOL) and maintains a $0.4 price target.
May 14, 2024 | 3:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson reaffirmed a Speculative Buy rating on Biolase, with a steady price target of $0.4, indicating potential upside.
The reaffirmation of a Speculative Buy rating and the maintenance of a price target by a reputable analyst can lead to increased investor confidence and potential short-term price appreciation. The specific mention of Biolase and the reiteration of the price target suggest a positive outlook on the stock's performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100